575 abstracts found.



Results filter

Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study

Year:

Session type:

Yohann Loriot1,Jonathan E. Rosenberg2,Thomas Powles3,Andrea Necchi4,Syed A. Hussain5,Rafael Morales6,Margitta Retz7,Günter Niegisch8,Ignacio Durán9,Christine Théodore10,Jose Luis Perez Gracia11,Enrique Grande12,Annchristine Thåström13,Bradford Danner13,Sanjeev Mariathasan13,Oyewale Abidoye13,Michiel van der Heijden14
1Gustave Roussy, Villejuif, France,2Memorial Sloan Kettering Cancer Center, New York, NY, USA,3Barts Cancer Institute, Queen Mary University of London, London, UK,4Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy,5University of Liverpool, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK,6Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain,7Urologische Klinik und Poliklinik, Technische Universität München, Munich, Germany,8Department of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany,9Hospital Universitario Virgen del Rocio, Instituto de Biomedicina, Sevilla, Spain,10Department of Oncology, Hôpital Foch, Suresnes, France,11Clínica Universidad de Navarra, Pamplona, Spain,12Hospital Universitario Ramón y Cajal, Madrid, Spain,13Genentech, Inc., South San Francisco, CA, USA,14Netherlands Cancer Institute, Amsterdam, the Netherlands

IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)

Year:

Session type:

Joaquim Bellmunt1,Arjun Balar2,Matthew D. Galsky3,Yohann Loriot4,Christine Théodore5,Enrique Grande6,Daniel Castellano7,Margitta Retz8,Günter Niegisch9,Sergio Bracarda10,Andrea Necchi11,Ulka Vaishampayan12,Srikala S. Sridhar13,Bernhard J. Eigl14,Syed A. Hussain15,Michiel van der Heijden16,Bradford Danner17,Sanjeev Mariathasan17,Oyewale Abidoye17,Jonathan E. Rosenberg18
1Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA,2Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA,3Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA,4Gustave Roussy, Villejuif, France,5Department of Oncology, Hôpital Foch, Suresnes, France,6Hospital Universitario Ramón y Cajal, Madrid, Spain,7Doce de Octubre University Hospital, Madrid, Spain,8Urologische Klinik und Poliklinik, Technische Universität München, Munich, Germany,9Department of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany,10USL Toscana Sud-Est Ospedale San Donato, Arezzo, Italy,11Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy,12Karmanos Cancer Institute, Detroit, MI, USA,13Princess Margaret Cancer Center, Toronto, ON, Canada,14BCCA Vancouver Cancer Centre, Vancouver, Canada,15University of Liverpool, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK,16Netherlands Cancer Institute, Amsterdam, the Netherlands,17Genentech, Inc., South San Francisco, CA, USA,18Memorial Sloan Kettering Cancer Center, New York, NY, USA

CRUK SMP2: NGS of FFPE-extracted DNA from advanced NSCLC leading to selection of patients for The National Lung Matrix Trial

Year:

Session type:

Sumi Subramaniam1,Helen Pitman1,David Gonzalez de Castro2,Lisa Thompson3,Jenny Bell4,Pauline Rehal5,Rachel Butler6,Alessandro Rettino5,Ian Williams6,Helen Roberts6,Manisha Maurya3,Suzanne MacMahon3,Gary Middleton7,Rowena Sharpe1,Ian Walker1,Peter Johnson1,Emily Howlett1
1Cancer Research UK,2Queen's University Belfast,3Royal Marsden NHS Foundation Trust,4West Midlands Regional Genetics Laboratory,5West Midlands Regional Genetics Laboratory, Birmingham,6All Wales Medical Genetics Service, Cardiff,7University Hospitals Birmingham NHS Foundation Trust

A South Yorkshire audit to evaluate first line palliative treatment with Herceptin and doublet chemotherapy in patients with HER2 positive gastric or gastro-oesophageal cancer

Year:

Session type:

Stephen Robinson1,Joanne Hornbuckle1,Kathleen Dunn1,Suzanne Darby1,Jon Wadsley2,Fiona Taylor1
1Sheffield Teaching Hospitals NHS Foundation Trust,2Weston Park Hospital

Differential DNA methylation at the promoters of VEGF-B and VEGF-C is prognostic for clinical outcomes in ICON7 ovarian cancer patients and VEGF-C regulates cancer stem cell activity

Year:

Session type:

Alun Passey1,Charlotte Wilhelm-Benartzi1,Nahal Masrour1,Maria Pilar Barretina Ginesta2,Andy Embleton3,Rick Kaplan3,Anna de Fazio4,Bob Brown1
1Imperial College London,2Grupo Espagnol de Investigacion en Cancer de Ovario,3MRC Clinical Trials Unit, ICON7,4Australia New Zealand Gynaecological Oncology Group

When the breast surgeons take the lead in genetic testing, how satisfied are the patients?

Year:

Session type:

Hiba El Hage Chehade1,Christina W K Choy1,Amtul R Carmichael1,Aisling Manson1,Abdul Kasem1,Kefah Mokbel1
1The Princess Grace Hospital

Primary pulmonary pathology detected by screening for ovarian cancer using serial serum CA 125 assay in a risk of ovarian cancer (ROCA) based trial

Year:

Session type:

Robert Woolas1,Steven Skates2,Andy Ryan3,Alex Gentry-Maharaj4,Jaterpinder Kalsi4,Siti Spaun5,James Woolas5,Usha Menon4,Ian Jacobs6
1NHS,2Harvard Medical School, Boston USA,3Womens Cancer, UCL EGA Institute for Womens Health, London, UK,4Womens Cancer, UCL EGA Institute for Womens Health, London UK,5Portsmouth Hospitals,6University of New South Wales

Selection of PKH26HI quiescent populations selects for cells with insensitivity to TRAIL

Year:

Session type:

Amal Ali Arhoma1,ANDY Chantry2,SARAH HAYWOOD-SMALL1,NEIL Cross1
1Sheffield Hallam University,2Department of Oncology, The Medical School, Sheffield University

Characteristics of older patients receiving cancer chemotherapy

Year:

Session type:

Mary Denholm1,Francesca Holt1,Pippa Corrie1
1Cambridge University Hospital NHS Foundation Trust

A Retrospective Study of the use of Genomic Profiling in a Breast Cancer Screening Centre

Year:

Session type:

Peter Lion1,Susan Cleator1
1Imperial College Healthcare NHS Trust

Validation and comparison of a standardised ctDNA NGS assay across two laboratories

Year:

Session type:

Karen Howarth1,John Calaway1,Shannon Blais1,Sarah Smalley1,Greg Jones1,Davina Gale1,Vincent Plagnol1,Andrew Lawson1,Michelle Pugh1,Mikidache Madi1,Bradley Durham1,Vasudev Kumanduri1,Esther Musgrave-Brown1,Samuel Woodhouse1,Tim Forshew1,Nitzan Rosenfeld1,James Clark1
1Inivata

TMEPAI, A Novel Therapeutic Target in Triple Negative Breast Cancer Prevention and Therapy

Year:

Session type:

Prajjal Singha1,Srilakshmi Pandeswara2,Manjeri Venkatachalam3,Pothana Saikumar3
1University of Texas health Science center at San Antonio,2Department of Med/Hematology & Med Oncology. University of Texas Health Science Center at San Antonio, Texas, USA,3Department of Pathology, University of Texas Health Science Center at San Antonio, Texas, USA

Extralevator Abdomino-Perineal Resection Of The Rectum Should Not Be The Default Operation For Low Rectal Cancer

Year:

Session type:

Anwar Hussain1,Andrew Torrance1,Saad Azhar1
1University Hospitals of North Midlands Stoke-on-Trent

Clinical characteristics and treatment outcome of small cell cancer of the bladder; results from a 10-year experience from 3 UK cancer centres

Year:

Session type:

Caroline Chau1,Rosalind Jarvis2,Chern Lee3,Hannah Markham3,Wessam Al-Utayem2,Neerja Agarwal4,Tom Geldart2,Simon Crabb5
1Portsmouth Hospital Trust,2Dorset Cancer Centre, Poole Hospital NHS Foundation Trust,3University Hospital Southampton NHS Foundation Trust,4Porstmouth Hospital NHS Trust,5Cancer Sciences Unit, University of Soutahmpton Faculty of Medicine

A novel NGS based cancer genetic testing solution on high-throughput sequencer BGISEQ-500

Year:

Session type:

Shida Zhu1,Jing Yu1,Libin Shao1,Ao Chen2,Zhe Wang3,Hui Jiang1
1BGI,2CGI China,3BGI-Dx

Prostate Cancer treated with External Beam Radiation therapy; Exploring Dose, Biomarkers and Quality of Life

Year:

Session type:

Sarah O S Osman1,Simon Horn2,Darren Brady2,Karen Crowther3,Ciara A Lyons2,Suneil Jain2,Alan R Hounsell4,Kevin M Prise2,Conor K McGarry5,Joe M O’Sullivan2
1Queen's University Belfast,2Queen’s University Belfast, Centre for Cancer Research and Cell Biology, Belfast, United Kingdom,3Belfast Health and Social Care Trust, Northern Ireland Cancer Centre, Belfast, United Kingdom.,44Belfast Health and Social Care Trust, Radiotherapy Physics- Northern Ireland Cancer Centre, Belfast, United Kingdom,5Belfast Health and Social Care Trust, Radiotherapy Physics- Northern Ireland Cancer Centre, Belfast, United Kingdom

A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory DLBCL

Year:

Session type:

Toby Eyre1,Catherine Hildyard1,Angela Hamblin1,Kim Linton2,Andrew Pettitt3,Simon Rule4,Kate Cwynarski5,Sally Barrington6,David Wrench7,Andrew Davies8,Graham Collins1
1Oxford University Hospitals NHS Trust,2Department of Medical Oncology, The Christie Hospital NHS Trust, Wimslow Road, Manchester, M20 4BX, UK.,3Royal Liverpool and Broadgreen University Hospitals NHS Trust, Prescot Street, Liverpool, Merseyside L7 8XP, UK.,4Derriford Combined Laboratories, Derriford Hospital, Derriford Road, Plymouth, PL6 8DH, UK,5Department of Haematology, University College London Hospitals, 235 Euston Road, London, NW1 2BU,6Clinical PET Centre, St Thomas’ Hospital, Westminster Bridge Road, London, SE1 7EH,7Department of Haematology, Guy’s and St Thomas’ Hospital, Westminster Bridge Road, London, SE1 7EH,8Department of Medical Oncology, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD

Use of implantable fiducial markers for IGRT in prostate cancer, North Wales experience

Year:

Session type:

Joseph Lunn1,Rebecca Crawford1,Karen Thomas1,Carmel Barnett1,Cathryn Wood1,Julie Marrs1,Jessica France1,Susan Owen1,Sally Jones1,Jaap Vaarkamp1,Iqbal Shergill1,Zulfiqar Ali1,Muhammad Farooq Latif1
1BCUHB

Differentiating tumour progression from pseudoprogression in patients with glioblastoma using multiparametric MRI imaging: data from Barts Health NHS trust London

Year:

Session type:

Rachel Lewis1,Ashwin Bhandari2,Edward McKintosh2,Piers Plowman2,Joe Lansley2,Jane Evanson3,Anant Krishnan4,Mahmoud Ali Zohree Ali4
1Barts Hospital,2Barts Health NHS trust, London,3Barts Health NHS trust London,4Barts Health NHS trust

Enzalutamide Effectiveness and Tolerability in Patients with Castration Resistant Prostate Cancer. Our Experience

Year:

Session type:

Loaie El-Helw1,Salil Vengalil2,Rajanee Bhana2,Sandra Heuschkel2,Fawzi Adab2
1Royal Stoke Hospital, UK and Mansoura University, Egypt,2The Royal Stoke hospital, Stoke-On-Trent

Exploration of glioblastoma biology with liquid biopsy reveals a specific ctDNA fragmentation pattern.

Year:

Session type:

Florent Mouliere1,Richard Mair1,Christopher Smith1,Dineika Chandrananda1,Francesco Marass1,Davina Gale1,James Morris1,Dana Tsui1,Alan Wright1,Charlie Massie2,Colin Watts3,Nitzan Rosenfeld1,Kevin Brindle1
1Cancer Research UK Cambridge Institute, University of Cambridge,2University of Cambridge,3Department of Clinical Neurosciences, University of Cambridge

Establishing a Platform Trial in the UK – early experiences of set-up and recruitment to the Add-Aspirin Trial

Year:

Session type:

Christopher Coyle1,Anna Thomason1,Marta Campos1,Ruth Langley1
1MRC CTU at UCL

Audit assessing correlation between pre-operative MRI stage and histology findings post-laparoscopic radical prostatectomy.

Year:

Session type:

Madhavi Natarajan1,Omar Al-Kadhi1,Robert Mills1
1NHS

Development of a hypoxia gene signature as a biomarker for treatment stratification in prostate cancer

Year:

Session type:

Becky Bibby1,Darren Roberts1,Yang Lingjian1,Syed Haider2,Wei-Chen Cheng2,Paul O'Reilly3,Darragh McArt3,Ananya Choudhury1,Francesca Buffa2,Catharine West1
1University of Manchester,2University of Oxford,3Queens University Belfast

A multicentre cohort study to redefine and validate pathological assessment of response to neoadjuvant therapy in treated oesophagogastric adenocarcinoma

Year:

Session type:

Megan A Lloyd1,Fergus Noble1,Rob Walker1,Damien McManus2,Richard Turkington2,Matt Bedford3,Ewen Griffiths3,John Whiting3,Barbara Nutzinger4,Nicola Grehan4,J Robert O'Neill5,Richard JE Skipworth5,Vicki Save5,Sutaria Rupesh6,Stuart Mercer6,John H Saunders7,Irshad N Soomro7,Simon L Parsons7,Rebecca C Fitzgerald8,Timothy J Underwood9
1Cancer Sciences Unit, University of Southampton,2Centre for Cancer Research and Cell Biology, Queen’s University Belfast,3University Hospitals Birmingham NHS Foundation Trust,4on behalf of OCCAMS, Hutchison/MRC Cancer Unit, University of Cambridge,5Royal Infirmary of Edinburgh,6Portsmouth NHS Trust,7Nottingham University Hospitals NHS Trust,8on behalf of OCCAMS, Hutchison/MRC Cancer Unit, University of Cambridge, Cambridge, UK,9on behalf of OCCAMS, Cancer Sciences Unit, University of Southampton

REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULT DE NOVO ACUTE LYMPHOBLASTIC LEUKEMIA: A PROSPECTIVE STUDY FROM THE UKALL14 TRIAL (ISRCTN 66541317)

Year:

Session type:

Dina Okasha1,Amy Kirkwood2,Mhairi Copland3,Emma Lawrie4,Andrew McMillan5,Tobias Menne6,Nick Morley7,Clare Rowntree8,Deborah Richardson9,Paul Smith4,Adele Fielding10,David Marks11
1Cancer Institute, UCL,2CRUK and UCL Cancer Trials Centre,3Paul O'Gorman Leukaemia Research Centre, University of Glasgow,4UCL Cancer Trials Centre,5Centre for Clinical Haematology, Nottingham City Hospitals NHS Trust,6Newcastle Upon Tyne Hospitals NHS Trust,7Royal Hallamshire Hospital Sheffield,8Heath Hospital, Cardiff,9University Hospitals Southampton,10Department of Hematology, UCL Cancer Institute,11University Hospitals Bristol NHS Trust

Colorectal Cancer: Defining the immunological targets of reactive disease

Year:

Session type:

Payalben Savaliya1,Viktoriya Boncheva2,Mark Tangney3,Gerald O'Sullivan3,Barbara Guinn1
1University of Bedfordshire,2University of Sussex,3University College Cork

Pharmacogenomics in children with cancer

Year:

Session type:

Christopher Barton1
1Alder Hey Children's Hospital

Surgical management and oncological outcomes can be enhanced with selective use of post-chemoradiotherapy MRI in patients with high risk rectal tumours

Year:

Session type:

Caitlin MacLeod1,Craig MacKay1,George Ramsay1,Steven Yul1,Graeme Murray1,Craig Parnaby1
1NHS Grampian

Survivin, Endoglin and WT1 are frequently expressed in adult B-cell acute lymphocytic leukaemia

Year:

Session type:

Payalben Savaliya1,Stephanie Bonney2,Laurence Orchard2,Ken Mills3,Kim Orchardc4,Barbara Guinn1
1University of Bedfordshire,2Laurence Orchardb,3Queen’s University Belfast,4Southampton University Hospital

Carcinoma of Unknown Primary: prognosis with and without chemotherapy in Lancashire/South Cumbria in 2015

Year:

Session type:

David Fyfe1,Catherine Thompson1,Sarah Moon1,Sin Lau2,Pavel Bezecny2,Ruth Board3,Catherine Mitchell3,Sarah Cotter1,Rachel Simpson1
1University Hospitals of Morecambe Bay,2Blackpool Victoria Hospital,3Lancashire Teaching Hospitals

Metabolism, methylation and malignancy of the prostate

Year:

Session type:

Charlie Massie1,Andy G. Lynch1,Ian G. Mills2,The ICGC Prostate UK Group3
1University of Cambridge,2Queen's University Belfast,3CRUK, ICG, UEA, UoC

Immunological function in patients with different neutrophil to lymphocyte ratios in patients receiving chemotherapy for advanced colorectal cancer.

Year:

Session type:

Samantha Turnbull1,Dr Emma West1,Miss Karen Scott1,Dr Jenny Seligmann1,Miss Emma Tidswell1,Professor Matt Seymour1,Professor Alan Melcher2,Dr Christy Ralph1
1University of Leeds,2Institute of Cancer Research

Disulfiram with or without metformin exhibits potent anti-cancer effects toward oesophageal squamous cell carcinoma in vivo.

Year:

Session type:

Rupal Jivan1,Jade Peres2,Leonard Damelin3,Sharon Prince2,Demetra Mavri-Damelin1
1University of the Witwatersrand,2University of Cape Town,3National Institute for Communicable Diseases

Rectal cancer resection: Laparoscopic versus open surgery

Year:

Session type:

Caitlin MacLeod1,Craig MacKay1,George Ramsay1,Steven Yule1,Graeme Murray1,Craig Parnaby1
1NHS Grampian

Iterative Data Multiplexing Identifies Therapeutic Candidates for Oral Squamous Cell Carcinoma

Year:

Session type:

Emma Shanks1,Matthew Davidson1
1Beatson Institute for Cancer Research

Cancer microvesicles induce Tissue Factor-related procoagulant activity in endothelial cells in vitro.

Year:

Session type:

M. Adeola Adesanya1,Leigh Madden2,Anthony Maraveyas1
1Hull York Medical school,2School of Biological, Biomedical and Environmental Sciences

Preoperative mapping and surgical technique for No Touch SMA first Pancreatico-duodenectomy: Initial experience

Year:

Session type:

Vivek Upasani1,Amer Aldouri2
1St James University Hospital,2St James University Hospital, Leeds

Poly lactic-co-glycolic acid controlled delivery of Disulfiram to target liver cancer stem-like cells

Year:

Session type:

Zhipeng Wang1,Vinodh Kannappan2,Jiao Tan3,Ying Liu3,Angel L Armesilla4,Xiuwu Bian3,Weiguang Wang4
1University of Wolverhampton,2Research Institute Health Care Science,3Institute of Pathology and Southwest Cancer Center, Third Military Medical University, Chongqing, China,4Research Institute in Healthcare Science, Faculty of Science & Engineering, University of Wolverhampton, Wolverhampton, UK

AMP-activated protein kinase expression in breast cancer in relation to obesity

Year:

Session type:

Kaltoom Al-Sakkaf1,Mohammed Hassan1,Hani Choudhry1,Laila Damnhory1,Jaudah Almaghrabi1,Alia Al-Dahlawi1,Mohammed Elshal1,Abdulrahman Al-Malki1,Sawsan Ashoor2,Pauline Dobson3,Barry Brown3
1King Abdulaziz university,2King Abdulaziz university hospital,3University of Sheffield

20-Hydroxyeicosatetraenoic acid and its cytochrome-P450 isoform expression are linked to tumor proliferation in bladder cancer cells (RT4)

Year:

Session type:

Yilun Zhang1,Victor Garcia2,Cheng-Chia Wu3,Michal Laniado Schwartzman4
1New York Medical College,2Dept of Pharmacology, Yale University, New Haven, CT,3Department of Medicine, Greenwich Hospital, Greenwich, CT,4Dept of Pharmacology, New York Medical College

In vivo Skin dose measurements using TLD for head and neck patients treated with IMRT and 3D-CRT

Year:

Session type:

Khaldoon Radaideh1
1Al Qassim University

Integrin signalling regulates YAP and TAZ to control skin homeostasis

Year:

Session type:

Zoé Vincent-Mistiaen1,Ahmed Elbediwy1,Bradley Spencer-Dene1,Richard Stone1,Stefan Boeing1,Stefanie Wculek <1,Julia Cordero2,Ee Hong Tan2,Rachel Ridgeway3,Val Brunton3,Erik Sahai1,Holger Gerhardt1,Axel Behrens1,Ilaria Malanchi1,Owen Sansom2,Barry Thompson1
1Francis Crick Institute,2Beatson Institute,3University of Edinburgh

Nucleoside-analogue tracing identifies a phenotypically distinct subpopulation of slow-cycling cells in high-grade serous ovarian cancer, providing an explaination for clinical relapse

Year:

Session type:

Douglas Hall1,Siru Virtanen1,John Stingl1,James Brenton1
1University of Cambridge / Cancer Research UK

Axl promotes metastasis of pancreatic cancer by regulating an EMT programm

Year:

Session type:

Lankhanh Trinh1,Dieter Saur1
1Rechts der Isar Hospital

Cten stimulates cell motility through Src signaling in colorectal cancer.

Year:

Session type:

Abdulaziz Asiri1,Maham Akhlaq1,Hannah Thorpe1,Mohammad‎ Ilyas1
1University of Nottingham

Searching for synthetically lethal drug-virotherapy combinations.

Year:

Session type:

Victoria Roulstone1
1Institute of Cancer Research

Administration-specific migration of Th1 cells modulates the host immune system, tumor microenvironment, and antitumoral efficiency during immunotherapy in pancreatic cancer

Year:

Session type:

Christoph Griessinger1,Andreas M. Schmid1,Barbara F. Schörg1,Dominik B.A. Krüger1,Daniel Bukala1,Birgit Fehrenbacher2,Ursula Kohlhofer3,Leticia Quintanilla-Martinez3,Martin Schaller2,Martin Röcken2,Bernd J. Pichler1,Manfred Kneilling1
1Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen,2Department of Dermatology, University of Tübingen,3Department of Pathology, University of Tübingen

NOTCH1 Mutations and Extracapsular Spread in Oral Squamous Cell Carcinoma Lymph Node Metastasis

Year:

Session type:

Priyanka Bhattacharya1,Janet Risk1,Jagjit Dhanda1,Richard Shaw1,Bryony Lloyd2,David Ross Sibson1
1University of Liverpool,2Unversity of Liverpool

miRNA inhibition as a potential tool to modulate drug response in cholangiocarcinoma (CCA)

Year:

Session type:

Pietro Carotenuto1,Rosantony Pandolfo2,Michele Ghidini2,Maria Chiara Previdi2,Matteo Fasan3,Caterina Vicentini4,Robert Te Poele2,Paul Clarke2,Else Bosma2,Andrea Lampis2,Jens Hahne2,Francesco Trevisani2,Luke Boulter5,Rachel Guest6,Stuart Forbes6,Guido Torzilli7,Alessandro Zerbi8,Lorenza Rimassa7,Armando Santoro7,Massimo Roncalli7,Aldo Scarpa9,Nicola Valeri10,Paul Workman2,Chiara Braconi10
1The Institute of Cancer Research,2The Institute of Cancer Research, London, UK,3Dpt of Medicine, University of Padua, Padua, IT,4Dpt of Pathology, University of Verona, Verona, IT; Dpt of Medicine, University of Padua, Padua, IT,5MRC Human Genetics Unit MRC IGMM, University of Edinburgh,6MRC Centre for Inflammation Research, University of Edinburgh,7Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano (Milan), Italy,8The Royal Marsden NHS Trust London and Surrey, UK,9Dpt of Pathology, University of Verona, Verona, IT,10ICR; The Royal Marsden NHS Trust London and Surrey, UK